TriSalus Life Sciences Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
Nine months ended September 30, 2024 and 2023
(unaudited, in thousands except share data)
| Nine months ended September 30, 2024 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred stock · Common stock · Additional paid-in capital · Accumulated deficit · Total | |||||||||||||
| Shares · Amount · Shares · Amount | |||||||||||||
| At December 31, 2023 | 4,015,002 | $— | 26,413,213 | $2 | $222,437 | $(249,504) | $(27,065) | ||||||
| Exercise of options | — | — | (4,941) | (1) | — | 7 | — | 7 | |||||
| Stock-based compensation | — | — | — | — | 1,086 | — | 1,086 | ||||||
| Proceeds from sale of common stock | — | — | 350,000 | — | 3,141 | — | 3,141 | ||||||
| Net loss | — | — | — | — | — | (13,206) | (13,206) | ||||||
| At March 31, 2024 | 4,015,002 | $— | 26,758,272 | $2 | $226,671 | $(262,710) | $(36,037) | ||||||
| Exercise of options | — | — | 1,191 | — | 5 | — | 5 | ||||||
| Stock-based compensation | — | — | — | — | 1,275 | — | 1,275 | ||||||
| Proceeds from sale of common stock | — | — | 400,000 | — | 3,602 | — | 3,602 | ||||||
| Record exchange warrants | — | — | — | — | 11,923 | — | 11,923 | ||||||
| Record issuance costs | — | — | — | — | (1,699) | — | (1,699) | ||||||
| Net loss | — | — | — | — | — | (4,332) | (4,332) | ||||||
| At June 30, 2024 | 4,015,002 | $— | 27,159,463 | $2 | $241,777 | $(267,042) | $(25,263) | ||||||
| Exercise of options | — | — | 660 | — | 2 | — | 2 | ||||||
| Stock-based compensation | — | — | — | — | 1,383 | — | 1,383 | ||||||
| Proceeds from sale of common stock | — | — | 1,166,530 | 1 | 5,842 | — | 5,843 | ||||||
| Issuance of common stock for exchange warrants | — | — | 2,110,366 | — | — | — | — | ||||||
| Preferred stock conversion | (30,000) | — | 32,645 | — | — | — | — | ||||||
| Net loss | — | — | — | — | — | (2,399) | (2,399) | ||||||
| At September 30, 2024 | 3,985,002 | $— | 30,469,664 | $3 | $249,004 | $(269,441) | $(20,434) | ||||||
(1)Amount reflects 2,906 shares issued for option exercises and 7,847 shares returned from options exercised in 2023 to correct clerical error.
| Nine months ended September 30, 2023 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred stock · Common stock · Additional paid-in capital · Accumulated deficit · Total | |||||||||||||||||
| Shares · Amount · Shares · Amount | |||||||||||||||||
| December 31, 2022 | — | $— | 347,926 | $— | $10,028 | $(186,358) | $(176,329) | ||||||||||
| Exercise of options | — | — | 95,842 | — | 50 | — | 50 | ||||||||||
| Stock-based compensation | — | — | — | — | 73 | — | 73 | ||||||||||
| Deemed dividend | — | — | — | — | 959 | (959) | — | ||||||||||
| Net loss | — | — | — | — | — | (8,313) | (8,313) | ||||||||||
| At March 31, 2023 | — | $— | 443,769 | $— | $11,110 | $(195,630) | $(184,519) | ||||||||||
| Exercise of options | — | — | 4,592 | — | 16 | — | 16 | ||||||||||
| Stock-based compensation | — | — | — | — | 69 | — | 69 | ||||||||||
| Deemed dividend | — | — | — | — | 2,022 | (2,022) | — | ||||||||||
| Net loss | — | — | — | — | — | (13,985) | (13,985) | ||||||||||
| At June 30, 2023 | — | $— | 448,361 | $— | $13,217 | $(211,637) | $(198,419) | ||||||||||
| Exercise of options | — | $— | 50,646 | $— | $29 | $— | $29 | ||||||||||
| Stock-based compensation | — | — | — | — | 259 | — | 259 | ||||||||||
| Impact of Business Combination | |||||||||||||||||
| Conversion of redeemable convertible preferred stock into common stock in connection with the Business Combination | — | — | 21,500,867 | 2 | 204,234 | — | 204,236 | ||||||||||
| Assumption of warrants to purchase common stock in connection with the Business Combination | — | — | — | — | (2,568) | — | (2,568) | ||||||||||
| Issuance of common stock upon closing the Business Combination, net of expenses | — | — | 4,316,808 | — | 957 | — | 957 | ||||||||||
| Contingent earnout liability recognized upon closing of the Business Combination | — | — | — | — | (28,927) | — | (28,927) | ||||||||||
| Assumption of preferred stock in connection with the Business Combination | 4,015,002 | 1 | — | — | 34,150 | — | 34,151 | ||||||||||
| Net loss | — | — | — | — | — | (1,425) | (1,425) | ||||||||||
| At September 30, 2023 | 4,015,002 | $1 | 26,316,682 | $2 | $221,351 | $(213,062) | $8,292 | ||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.